[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100440711":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":20,"studyPopulation":13,"armGroups":21,"interventions":28,"overallOfficials":34,"centralContacts":13,"locations":38,"responsibleParty":72,"collaborators":13,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":13,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":13,"maxAge":13,"enrollmentInfo":82,"targetDuration":13,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":41,"whyStopped":13,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"The Foundation for Orthopaedics and Regenerative Medicine","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Safety (adverse events)","Clinical monitoring of possible adverse events or complications","Four year follow-up",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE","Studies have shown that stem cell treatment is safe and efficacious for the treatment of Lupus. This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for the treatment of Lupus. Patients with Lupus will receive a single intravenous infusion of UC-MSCs. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.\n\nFor patients with more severe disease an autologous T-Cell vaccine will be utilized created from the patient's own cells obtained by apheresis.",[22],{"label":23,"type":24,"description":25,"interventionNames":26},"Treatment Group (AlloRx)","EXPERIMENTAL","Single intravenous infusion of 100 million cells",[27],"Biological: AlloRx",[29],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":13},"BIOLOGICAL","AlloRx","cultured allogeneic adult umbilical cord derived mesenchymal stem cells",[23],[35],{"name":36,"affiliation":5,"role":37},"Chadwick Prodromos, MD","PRINCIPAL_INVESTIGATOR",[39,57],{"facility":40,"status":41,"city":42,"state":13,"zip":13,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Medical Surgical Associates Center","RECRUITING","St John's","Antigua and Barbuda","AG",{"type":46,"coordinates":47},"Point",[48,49],-61.84329,17.12096,{"lat":49,"lon":48},[52],{"name":53,"role":54,"phone":55,"phoneExt":13,"email":56},"Chadwick Prodromos, M.D.","CONTACT","8476996810","care@thepsci.com",{"facility":58,"status":41,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Athens Beverly Hills Medical Group","Glyfada","Athens","16675","Greece","GR",{"type":46,"coordinates":65},[66,67],23.75802,37.86289,{"lat":67,"lon":66},[70],{"name":53,"role":54,"phone":55,"phoneExt":13,"email":71},"Care@thepsci.com",{"type":73,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100440711","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-intravenous-infusion-for-lupus-100440711",false,"NCT05018858","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Lupus","Inclusion Criteria:\n\n* Diagnosis of Lupus\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur","ALL",{"count":83,"type":84},15,"ESTIMATED","INTERVENTIONAL",[87],"PHASE1","This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Lupus",[90],"Lupus",[90,92,93],"Lupus Arthritis","stem cell treatment","2025-04-04",{"date":96,"type":97},"2025-04-08","ACTUAL",{"date":99,"type":84},"2025-12",{"date":101,"type":84},"2028-10",{"name":5,"class":6},2]